tiprankstipranks
Cross Country Healthcare (CCRN)
NASDAQ:CCRN
Want to see CCRN full AI Analyst Report?

Cross Country Healthcare (CCRN) AI Stock Analysis

267 Followers

Top Page

CCRN

Cross Country Healthcare

(NASDAQ:CCRN)

Select Model
Select Model
Select Model
Neutral 60 (OpenAI - 5.2)
Rating:60Neutral
Price Target:
$14.00
▲(64.90% Upside)
Action:Reiterated
Date:05/09/26
The score is held back primarily by deteriorating operating performance (revenue declines, margin compression, and losses), while a strong, debt-free balance sheet and positive cash generation provide stability. Technicals are supportive but overbought, valuation support is limited due to negative earnings, and the earnings call plus the announced take-private deal modestly improve the outlook while still carrying execution/closing risks.

Cross Country Healthcare (CCRN) vs. SPDR S&P 500 ETF (SPY)

Cross Country Healthcare Business Overview & Revenue Model

Company Description
Cross Country Healthcare, Inc. provides talent management and other consultative services for healthcare clients in the United States. The company operates in two segments, Nurse and Allied Staffing and Physician Staffing. The Nurse and Allied Sta...
How the Company Makes Money
Cross Country Healthcare primarily makes money by charging healthcare providers and other clients for workforce solutions, earning revenue from the spread between what it bills clients and what it pays clinicians and other placed professionals, pl...

Cross Country Healthcare Earnings Call Summary

Earnings Call Date:Mar 04, 2026
(Q4-2025)
|
% Change Since: |
Next Earnings Date:Aug 05, 2026
Earnings Call Sentiment Neutral
The call presents a balanced picture: the company reported significant revenue declines and a large noncash impairment that pressured profitability in 2025, but it also emphasized a strong balance sheet (no debt, $109M cash), meaningful cost reductions, accelerating weekly production and strategic investments in proprietary technology (Intellify/Xperience) and AI. Management provided cautious near-term guidance (Q1 revenue $235M–$240M; adjusted EBITDA ~$4M–$5M) while outlining a credible path to recovery — targeting a >$1B revenue run-rate and 4%–5% adjusted EBITDA margin by year-end 2026 — backed by redeployed cost savings, headcount optimization, and growth in higher-margin segments (home-based and education). Given the material past declines and impairment but clear remediation plans, the tone is cautiously optimistic with balanced risks and opportunities.
Positive Updates
Strong balance sheet and capital flexibility
Ended Q4 with $109 million in cash and no debt, enabling discretionary deployment of capital. Completed share repurchases (December: >800,000 shares for $6.8M; additional ~486,000 shares purchased in Q1). Generated $18M cash from operations in Q4 and $48M for the full year.
Negative Updates
Material revenue declines
Consolidated Q4 revenue $237M, down 5% sequentially and 24% year-over-year. Full year revenue $1.05B, down 22% YoY. The declines are largely attributable to normalization of contingent utilization across core Nurse and Allied businesses (notably Travel).
Read all updates
Q4-2025 Updates
Negative
Strong balance sheet and capital flexibility
Ended Q4 with $109 million in cash and no debt, enabling discretionary deployment of capital. Completed share repurchases (December: >800,000 shares for $6.8M; additional ~486,000 shares purchased in Q1). Generated $18M cash from operations in Q4 and $48M for the full year.
Read all positive updates
Company Guidance
Management guided Q1 2026 revenue of $235–$240 million, adjusted EBITDA of $4–$5 million (≈2% margin) and adjusted EPS of a loss of $0.04–$0.06 on ~31.5 million shares, assuming gross margin of 19.5%–20%, net interest income of $0.3 million, depreciation & amortization of $4 million, stock‑based compensation of $1.3 million, a tax provision of ~$0.4 million and a ~$2 million payroll‑tax headwind; they also reiterated a 2026 exit target of a revenue run‑rate north of $1.0 billion (Q4 revenue >$250 million) and an adjusted EBITDA margin of 4%–5%.

Cross Country Healthcare Financial Statement Overview

Summary
Financials are mixed: the income statement is the main drag (sharp revenue declines, margin compression, and deep net losses in TTM), partially offset by a very low-debt balance sheet and still-positive operating/free cash flow that supports near-term stability.
Income Statement
28
Negative
Balance Sheet
78
Positive
Cash Flow
64
Positive
Breakdown
Income Statement
Total Revenue
Gross Profit
EBITDA
Net Income
Balance Sheet
Total Assets
Cash, Cash Equivalents and Short-Term Investments
Total Debt
Total Liabilities
Stockholders Equity
Cash Flow
Free Cash Flow
Operating Cash Flow
Investing Cash Flow
Financing Cash Flow

Cross Country Healthcare Technical Analysis

Technical Analysis Sentiment
Positive
Last Price8.49
Price Trends
50DMA
10.35
Positive
100DMA
9.53
Positive
200DMA
10.79
Positive
Market Momentum
MACD
0.92
Negative
RSI
77.57
Negative
STOCH
84.57
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CCRN, the sentiment is Positive. The current price of 8.49 is below the 20-day moving average (MA) of 11.53, below the 50-day MA of 10.35, and below the 200-day MA of 10.79, indicating a bullish trend. The MACD of 0.92 indicates Negative momentum. The RSI at 77.57 is Negative, neither overbought nor oversold. The STOCH value of 84.57 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CCRN.

Cross Country Healthcare Peers Comparison

Overall Rating
UnderperformOutperform
Sector (―)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
68
Neutral
$1.75B20.743.88%56.69%-15.92%
62
Neutral
$1.12B2.87-4.98%19.87%79.93%
60
Neutral
$423.56M-17.34-27.10%-20.37%-479.68%
56
Neutral
$1.45B1.10-146.01%-2.82%-45.70%
55
Neutral
$984.09M-9.24-9.20%14.13%62.92%
41
Neutral
$394.57M-0.165.89%-2.87%
* Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
CCRN
Cross Country Healthcare
13.11
-0.66
-4.79%
AMN
AMN Healthcare Services
26.86
4.75
21.48%
CYH
Community Health
2.81
-1.14
-28.86%
ASTH
Astrana Health
38.76
13.57
53.87%
INNV
InnovAge Holding
7.51
3.41
83.17%
AGL
Agilon Health
80.94
22.19
37.77%

Cross Country Healthcare Corporate Events

Business Operations and StrategyStock BuybackDelistings and Listing ChangesFinancial DisclosuresM&A Transactions
Cross Country Healthcare Reports Q1 Loss Amid Privatization Deal
Negative
May 7, 2026
Cross Country Healthcare reported first-quarter 2026 results on May 7, 2026, with consolidated revenue of $241.1 million, down 18% year over year but up 2% sequentially, and a net loss attributable to common stockholders of $4.3 million, wider tha...
Business Operations and StrategyDelistings and Listing ChangesM&A TransactionsShareholder Meetings
Cross Country Healthcare to Be Acquired by Knox Lane
Positive
May 7, 2026
On May 6, 2026, Cross Country Healthcare agreed to be acquired by Knox Lane in an all-cash deal that values the healthcare workforce solutions company at about $437 million, or $13.25 per share, representing a 31% premium to its May 6 close and a ...
Financial Disclosures
Cross Country Healthcare Schedules Q1 2026 Earnings Release
Neutral
Apr 17, 2026
On April 17, 2026, Cross Country Healthcare announced plans to release its first quarter 2026 financial results after the market close on Thursday, May 7, 2026. The company will host a quarterly earnings conference call that same day at 5:00 p.m. ...
Executive/Board Changes
Cross Country Healthcare Names Amiee Hawkins Chief Operating Officer
Positive
Mar 30, 2026
Cross Country Healthcare, Inc. announced that its Board of Directors approved the appointment of long-time executive Amiee Hawkins as Chief Operating Officer on March 25, 2026, with the role effective March 28, 2026. Hawkins, who joined the compan...
Business Operations and StrategyExecutive/Board Changes
Cross Country Healthcare CIO Departs, Assumes Advisory Role
Neutral
Mar 17, 2026
Cross Country Healthcare, Inc. reported that, effective March 10, 2026, Phil Noe ceased serving as its Chief Information Officer, and on March 16, 2026, the company entered into a Separation Agreement and an Independent Contractor Agreement with h...
Executive/Board Changes
Cross Country Healthcare Announces Key Executive Leadership Changes
Neutral
Mar 10, 2026
Cross Country Healthcare, Inc. announced that, effective March 10, 2026, Senior Vice President and Chief Accounting Officer James V. Redd III and Chief Information Officer Phil Noe ceased serving in their respective roles, with the company stating...
Business Operations and StrategyStock BuybackFinancial Disclosures
Cross Country Healthcare Reports 2025 Results Amid Market Challenges
Negative
Mar 4, 2026
Cross Country Healthcare reported that on March 4, 2026, it released fourth-quarter and full-year 2025 results marked by a 24% year-over-year revenue decline in the quarter to $236.8 million and a 22% drop for the year to $1.05 billion, alongside ...
Business Operations and Strategy
Cross Country Healthcare Plans Targeted March Investor Conference Outreach
Positive
Feb 23, 2026
On February 23, 2026, Cross Country Healthcare, Inc. announced that it will participate in two investor conferences in March, underscoring its effort to engage with the financial community and highlight its healthcare labor technology platform. Th...
Financial Disclosures
Cross Country Healthcare Schedules Q4 and 2025 Earnings Call
Neutral
Feb 12, 2026
Cross Country Healthcare, Inc., a technology-driven healthcare workforce solutions provider, specializes in an AI-enabled, cloud-based workforce and vendor management platform that supports hospitals and health systems in managing per diem staffin...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: May 09, 2026